our commitment to esg:

Our approach to sustainability and social responsibility

At Richmond Pharmacology, we are steadfast in our commitment to leading the way in environmental sustainability, social responsibility, and ethical governance.

Our Environmental, Social, and Governance (ESG) plan is a testament to this dedication, embodying our core values of Pioneers, Excellence, Efficiency, Respect, and Integrity.

This initiative not only aligns with our mission to advance medical research but also underscores our responsibility to our planet, our communities, and our future.

Our approach to sustainability and social responsibility

Our ESG plan is structured around three fundamental pillars: Environmental Sustainability, Social Empowerment, and Strong Governance.

Each pillar is designed to address the specific challenges and opportunities within our operations and the broader biomedical sector, with clear objectives, actionable strategies, and measurable outcomes.

pillar 1

Environmental Sustainability

Our planet's health is integral to our future. Richmond Pharmacology aims to significantly reduce our environmental impact through a series of targeted initiatives.

Icon depicting efficiency

energy efficiency

Implementation of energy-efficient lighting and appliances to reduce energy consumption.

icon depicting waste reduction

Waste Reduction

Comprehensive recycling programs and a commitment to digital transformation to minimise paper usage.

icon depicting carbon neutrality. plant circling the earth

Carbon Neutrality

A strategic roadmap to achieve a net-zero carbon footprint by 2030, reflecting our commitment to combating climate change.

pillar 2

Social Empowerment

At the heart of our ESG efforts is a commitment to fostering an inclusive, diverse, and equitable workplace and supporting the communities in which we operate.

Icon depicting diversity

Diversity and Inclusion

Initiatives to increase diversity in leadership positions, alongside programs to enhance workplace inclusivity and equity.

Icon depicting community operations

Community Engagement

Active involvement in local communities through volunteer programs, partnerships, and charitable contributions exceeding £17,000 in 2022.

pillar 3

Strong Governance

Ethical practices, transparency, and accountability are the cornerstones of our approach to governance.

Icon depicting a committee

ESG Committee

Establishment of a dedicated committee to oversee the implementation of our ESG initiatives, ensuring alignment with our core values and ethical standards.

Icon depicting metrics increasing

Community Engagement

Integration of ESG metrics into corporate performance reviews to track progress, drive accountability, and foster continuous improvement.

Expected Outcomes and Ongoing Progress

Our ESG initiatives are designed to create tangible benefits for our environment, our people, and our stakeholders. Expected outcomes include:

Enhanced environmental stewardship and reduced ecological footprint.

A more diverse, inclusive, and empowered workforce.

Stronger governance practices that uphold the highest standards of integrity and transparency.

We are committed to providing regular updates on our progress, challenges, and achievements in implementing our ESG plan. This transparency is key to our accountability and our pledge to not just promise but to act.

People working together on a problem
our commitment to esg:

Our approach to sustainability and social responsibility

We invite you to engage with our efforts and follow our progress as we pioneer a sustainable and responsible future in biomedical research.

Together, we can make a difference for our planet, our communities, and future generations.

At Richmond Pharmacology, we're not just conducting research; we're building a sustainable future.

For more information and to stay updated on our ESG journey:

Follow Our LinkedIn

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more


AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event